


CLAIMS

1. A compound of the formula



I

or a pharmaceutically acceptable salt thereof, wherein

A is $-CR_7$;

B is $-NR_1R_2$, $-CR_1R_2R_{11}$, $-C(=CR_2R_{12})R_1$, $-NHCHR_1R_2$, $-OCHR_1R_2$, $-SCHR_1R_2$, $-CHR_2OR_1$, $-CHR_1OR_2$, $-CHR_2SR_1$, $-C(S)R_2$, $-C(O)R_2$, $-CHR_2NR_1R_2$, $-CHR_1NHR_2$, $-CHR_1N(CH_3)R_2$, or $-NR_{12}NR_1R_2$;

Z is NH, O, S, $-N(C_1-C_2 \text{ alkyl})$, $-NC(O)CF_3$, or $-C(R_{13}R_{14})$, wherein R_{13} and R_{14} are each, independently, hydrogen, trifluoromethyl or methyl, or one of R_{13} and R_{14} is cyano and the other is hydrogen or methyl, or $-C(R_{13}R_{14})$ is a cyclopropyl group, or Z is nitrogen or CH and forms a five or six membered heterocyclic ring fused with R_5 , which ring optionally comprises two or three further hetero members selected independently from oxygen, nitrogen, NR_{12} , and $S(O)_m$, and optionally comprises from one to three double bonds, and is optionally substituted with halo, C_1-C_4 alkyl, $-O(C_1-C_4 \text{ alkyl})$, NH_2 , $NHCH_3$, $N(CH_3)_2$, CF_3 , or OCF_3 , with the proviso that said ring does not contain any $-S-S-$, $-S-O-$, $-N-S-$, or $-O-O-$ bonds, and does not comprise more than two oxygen or $S(O)_m$ heterologous members;

R_1 is $C(O)H$, $C(O)(C_1-C_6 \text{ alkyl})$, $C(O)(C_1-C_6 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, $C(O)(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, $C(O)(C_1-C_6 \text{ alkylene})(C_4-C_8 \text{ heterocycloalkyl})$, $-C(O)(C_3-C_8 \text{ cycloalkylene})(C_4-C_8 \text{ heterocycloalkyl})$, $C_1-C_6 \text{ alkyl}$, $C_3-C_8 \text{ cycloalkyl}$, $C_4-C_8 \text{ heterocycloalkyl}$, $-(C_1-C_6 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_1-C_6 \text{ alkylene})(C_4-C_8 \text{ heterocycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_4-C_8 \text{ heterocycloalkyl})$, or $-O\text{-aryl}$, or $-O-(C_1-C_6 \text{ alkylene})\text{-aryl}$; wherein said aryl, $C_4-C_8 \text{ heterocycloalkyl}$, $C_1-C_6 \text{ alkyl}$, $C_3-C_8 \text{ cycloalkyl}$, $C_3-C_8 \text{ cycloalkylene}$, and $C_1-C_6 \text{ alkylene}$ groups may each independently be optionally substituted with from one to six fluoro and may each independently be optionally substituted with one or two substituents R_8 independently selected from the group consisting of $C_1-C_4 \text{ alkyl}$, $-C_3-C_8 \text{ cycloalkyl}$, hydroxy, chloro, bromo, iodo, CF_3 , $-O-(C_1-C_6 \text{ alkyl})$, $-O-(C_3-C_5 \text{ cycloalkyl})$, $-O-CO-(C_1-C_4 \text{ alkyl})$, $-O-CO-NH(C_1-C_4 \text{ alkyl})$, $-O-CO-N(R_{24})(R_{25})$, $-N(R_{24})(R_{25})$, $-S(C_1-C_4 \text{ alkyl})$, $-S(C_3-C_5 \text{ cycloalkyl})$, $-N(C_1-C_4 \text{ alkyl})CO(C_1-C_4 \text{ alkyl})$, $-NHCO(C_1-C_4 \text{ alkyl})$, $-COO(C_1-C_4 \text{ alkyl})$, $-CONH(C_1-C_4 \text{ alkyl})$, $-CON(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$, CN, NO_2 , $-OSO_2(C_1-C_4 \text{ alkyl})$, $S^+(C_1-C_6 \text{ alkyl})(C_1-C_2 \text{ alkyl})I^-$,

-SO(C₁-C₄ alkyl) and -SO₂(C₁-C₄ alkyl); and wherein the C₁-C₆ alkyl, C₁-C₆ alkylene, C₅-C₈ cycloalkyl, C₅-C₈ cycloalkylene, and C₅-C₈ heterocycloalkyl moieties of R₁ may optionally independently contain from one to three double or triple bonds; and wherein the C₁-C₄ alkyl moieties and C₁-C₆ alkyl moieties of R₈ can optionally independently be substituted with hydroxy, amino, C₁-C₄ alkyl, aryl, -CH₂-aryl, C₃-C₅ cycloalkyl, or -O-(C₁-C₄ alkyl), and can optionally independently be substituted with from one to six fluoro, and can optionally contain one or two double or triple bonds; and wherein each heterocycloalkyl group of R₁ contains from one to three heteromoiety selected from oxygen, S(O)_m, nitrogen, and NR₁₂;

R₂ is hydrogen, C₁-C₁₂ alkyl, C₃-C₈ cycloalkyl, C₄-C₈ heterocycloalkyl, -(C₁-C₆ alkylene)(C₃-C₈ cycloalkyl), -(C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), -(C₁-C₆ alkylene)(C₄-C₈ heterocycloalkyl), -(C₃-C₈ cycloalkylene)(C₄-C₈ heterocycloalkyl), aryl, -(C₁-C₆ alkylene)aryl, or -(C₃-C₈ cycloalkylene)(aryl); wherein each of the foregoing R₂ groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, and C₁-C₆ alkyl, wherein one of said one to three substituents can further be selected from bromo, iodo, C₁-C₆ alkoxy, -OH, -O-CO-(C₁-C₆ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), -S(O)(C₁-C₆ alkyl), -S(O)₂(C₁-C₆ alkyl), S⁺(C₁-C₆ alkyl)(C₁-C₂ alkyl)I⁻, CN, and NO₂; and wherein the C₁-C₁₂ alkyl, -(C₁-C₆ alkylene), -(C₅-C₈ cycloalkyl), -(C₅-C₈ cycloalkylene), and -(C₅-C₈ heterocycloalkyl) moieties of R₂ may optionally independently contain from one to three double or triple bonds; and wherein each heterocycloalkyl group of R₂ contains from one to three heteromoiety selected from oxygen, S(O)_m, nitrogen, and NR₁₂;

or when R₁ and R₂ are as in -NHCHR₁R₂, -OCHR₁R₂, -SCHR₁R₂, -CHR₁R₂ or -NR₁R₂, R₁ and R₂ of B may form a saturated 5- to 8-membered ring which may optionally contain one or two double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen, S(O)_m, nitrogen or NR₁₂; and which carbocyclic ring can optionally be substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, CF₃, -O-(C₁-C₄ alkyl), -O-CO-(C₁-C₄ alkyl), -O-CO-NH(C₁-C₄ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -S(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)CO(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), CN, NO₂, -OSO₂(C₁-C₄ alkyl), -SO(C₁-C₄ alkyl), and -SO₂(C₁-C₄ alkyl), wherein one of said one to three substituents can further be selected from phenyl;

R₃ is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF₃, NH₂, NH(C₁-C₂ alkyl), N(CH₃)₂, -NHCOCF₃, -NHCH₂CF₃, S(O)_m(C₁-C₄ alkyl), CONH₂, -CONHCH₃, CON(CH₃)₂, -CF₃, or CH₂OCH₃;

R₄ is hydrogen, C₁-C₄ alkyl, C₃-C₅ cycloalkyl, -(C₁-C₄ alkylene)(C₃-C₅ cycloalkyl), -(C₃-C₅ cycloalkylene)(C₃-C₅ cycloalkyl), cyano, fluoro, chloro, bromo, iodo, -OR₂₄, C₁-C₆ alkoxy, -O-(C₃-C₅ cycloalkyl), -O-(C₁-C₄ alkylene)(C₃-C₅ cycloalkyl), -O-(C₃-C₅ cycloalkylene)(C₃-C₅ cycloalkyl), -CH₂SC(S)O(C₁-C₄ alkyl), -CH₂OF₃, CF₃, amino, nitro, -NR₂₄R₂₅, -(C₁-C₄ alkylene)-OR₂₄, -(C₁-C₄

alkylene)Cl, $-(C_1-C_4 \text{ alkylene})NR_{24}R_{25}$, $-NHCOR_{24}$, $-NHCONR_{24}R_{25}$, $-C=NOR_{24}$, $-NHNHR_{24}R_{25}$, $-S(O)_mR_{24}$, $-C(O)R_{24}$, $-OC(O)R_{24}$, $-C(O)CN$, $-C(O)NR_{24}R_{25}$, $-C(O)NHNHR_{24}R_{25}$, and $-COOR_{24}$, wherein the alkyl and alkylene groups of R_4 may optionally independently contain one or two double or triple bonds and may optionally independently be substituted with one or two substituents R_{10} independently selected from hydroxy, amino, $-NHCOCH_3$, $-NHCOCH_2Cl$, $-NH(C_1-C_2 \text{ alkyl})$, $-N(C_1-C_2 \text{ alkyl})(C_1-C_2 \text{ alkyl})$, $-COO(C_1-C_4 \text{ alkyl})$, $-COOH$, $-CO(C_1-C_4 \text{ alkyl})$, C_1-C_6 alkoxy, C_1-C_3 thioalkyl, cyano and nitro, and with one to four substituents independently selected from fluoro and chloro;

R_5 is aryl or heteroaryl and is substituted with from one to four substituents R_{27} independently selected from halo, C_1-C_{10} alkyl, $-(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkylene})(C_4-C_8 \text{ heterocycloalkyl})$, $-(C_3-C_8 \text{ cycloalkyl})$, $-(C_4-C_8 \text{ heterocycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_4-C_8 \text{ heterocycloalkyl})$, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, nitro, cyano, $-NR_{24}R_{25}$, $-NR_{24}COR_{25}$, $-NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, $-CO(NOR_{22})R_{23}$, $-CO_2R_{26}$, $-C=N(OR_{22})R_{23}$, and $-S(O)_mR_{23}$; wherein said C_1-C_{10} alkyl, C_3-C_8 cycloalkyl, $(C_1-C_4 \text{ alkylene})$, $(C_3-C_8 \text{ cycloalkyl})$, $(C_3-C_8 \text{ cycloalkylene})$, and $(C_4-C_8 \text{ heterocycloalkyl})$ groups can be optionally substituted with from one to three substituents independently selected from C_1-C_4 alkyl, C_3-C_8 cycloalkyl, $(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, C_1-C_4 haloalkyl, hydroxy, C_1-C_6 alkoxy, nitro halo, cyano, $-NR_{24}R_{25}$, $-NR_{24}COR_{25}$, $-NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, CO_2R_{26} , $-CO(NOR_{22})R_{25}$, and $-S(O)_mR_{23}$; and wherein two adjacent substituents of the R_5 group can optionally form a 5-7 membered ring, saturated or unsaturated, fused to R^5 , which ring optionally can contain one, two, or three heterologous members independently selected from O, $S(O)_m$, and N, but not any $-S-S-$, $-O-O-$, $-S-O-$, or $-N-S-$ bonds, and which ring is optionally substituted with C_1-C_4 alkyl, C_3-C_8 cycloalkyl, $-(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, C_1-C_4 haloalkyl, nitro, halo, cyano $-NR_{24}R_{25}$, $-NR_{24}COR_{25}$, $-NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, CO_2R_{26} , $-CO(NOR_{22})R_{25}$, or $-S(O)_mR_{23}$; wherein one of said one to four optional substituents R_{27} can further be selected from $-SO_2NH(C_1-C_4 \text{ alkyl})$, $-SO_2NH(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, $-SO_2NH(C_3-C_8 \text{ cycloalkyl})$, $-SO_2NH(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, $-SO_2N(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$, $-SO_2NH_2$, $-NHSO_2(C_1-C_4 \text{ alkyl})$, $-NHSO_2(C_3-C_8 \text{ cycloalkyl})$, $-NHSO_2(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, and $-NHSO_2(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$; and wherein the alkyl, and alkylene groups of R_5 may independently optionally contain one double or triple bond;

R_7 is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, $-O(C_1-C_2 \text{ alkyl})$, $-O(\text{cyclopropyl})$, $-COO(C_1-C_2 \text{ alkyl})$, $-COO(C_3-C_8 \text{ cycloalkyl})$, $-OCF_3$, CF_3 , $-CH_2OH$, or CH_2OCH_3 ;

R_{11} is hydrogen, hydroxy, fluoro, ethoxy, or methoxy;

R_{12} is hydrogen or C_1-C_4 alkyl;

EXPRESS MAIL NO. EL6281546205

R₂₂ is independently at each occurrence selected from hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₈ alkenyl, C₃-C₈ alkynyl, C₃-C₈ cycloalkyl, (C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), and (C₁-C₄ alkylene)(C₃-C₈ cycloalkyl);

5 R₂₃ is independently at each occurrence selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₈ alkoxyalkyl, C₃-C₈ cycloalkyl, -(C₁-C₄ alkylene)(C₃-C₈ cycloalkyl), -(C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), aryl, -(C₁-C₄ alkylene)aryl, piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, and thiomorpholine;


10 R₂₄ and R₂₅ are independently at each occurrence selected from hydrogen, -C₁-C₄ alkyl, C₁-C₄ haloalkyl, especially CF₃, -CHF₂, CF₂CF₃, or CH₂CF₃, -(C₁-C₄ alkylene)OH, -(C₁-C₄ alkylene)-O-(C₁-C₄ alkyl), -(C₁-C₄ alkylene)-O-(C₃-C₈ cycloalkyl), C₃-C₈ cycloalkyl, -(C₁-C₄ alkylene)(C₃-C₈ cycloalkyl), -(C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), -C₄-C₈ heterocycloalkyl, -(C₁-C₄ alkylene)(C₄-C₈ heterocycloalkyl), -(C₃-C₈ cycloalkylene)(C₄-C₈ heterocycloalkyl), aryl, and -(C₁-C₄ alkylene)(aryl), wherein the -C₄-C₈ heterocycloalkyl groups can each independently optionally be substituted with aryl, CH₂-aryl, or C₁-C₄ alkyl, and can optionally contain one or two
15 double or triple bonds; or, when R₂₄ and R₂₅ are as NR₂₄R₂₅, -C(O)NR₂₄R₂₅, -(C₁-C₄ alkylene)NR₂₄R₂₅, or -NHCONR₂₄R₂₅, then NR₂₄R₂₅ may further optionally form a 4 to 8 membered heterocyclic ring optionally containing one or two further hetero members independently selected from S(O)_m, oxygen, nitrogen, and NR₁₂, and optionally containing from one to three double bonds;

20 R₂₆ is independently at each occurrence selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₈ cycloalkyl, -(C₁-C₄ alkylene)(C₃-C₈ cycloalkyl), -(C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), aryl, and -(C₁-C₄ alkylene)(aryl); and

wherein each m is independently zero, one, or two,

25 with the proviso that heterocycloalkyl groups of the compound of formula I, II, or III do not comprise any -S-S-, -S-O-, -N-S-, or -O-O- bonds, and do not comprise more than two oxygen or S(O)_m heterologous members.

2. A compound according to claim 1 of the formula



I

, wherein

A is -CR₇;

30 B is -NR₁R₂, -CR₁R₂R₁₁, -C(=CR₂R₁₂)R₁, -NHCHR₁R₂, -OCHR₁R₂, -SCHR₁R₂, -CHR₂OR₁₂, -CHR₂SR₁₂, -C(S)R₂ or -C(O)R₂;

Z is NH, O, S, -N(C₁-C₂ alkyl) or -C(R₁₃R₁₄), wherein R₁₃ and R₁₄ are each, independently, hydrogen, trifluoromethyl or methyl, or one of R₁₃ and R₁₄ is cyano and the other is hydrogen or methyl;

5 R₁ is C₁-C₆ alkyl which may optionally be substituted with one or two substituents R₈ independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF₃, C₁-C₄ alkoxy, -O-CO-(C₁-C₄ alkyl), -O-CO-NH(C₁-C₄ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -S(C₁-C₄ alkyl), -N(C₁-C₄alkyl)CO(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl) and -SO₂(C₁-C₄ alkyl), and wherein said C₁-C₆ alkyl and the (C₁-C₄)alkyl moieties in the foregoing R₁ groups may optionally contain one carbon-carbon double or triple bond;

15 R₂ is C₁-C₁₂ alkyl, aryl or -(C₁-C₄ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or -(C₁-C₆ alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C₁-C₆ alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R₉ wherein R₉ is hydrogen or C₁-C₄ alkyl; and wherein each of the foregoing R₂ groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C₁-C₄ alkyl, or with one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -O-CO-(C₁-C₆ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), and -SO₂(C₁-C₄ alkyl), and wherein said C₁-C₁₂ alkyl and the C₁-C₄ alkylene moiety of said -(C₁-C₄ alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

25 or -NR₁R₂ or -CR₁R₂R₁₁ may form a saturated 5- to 8-membered carbocyclic ring which may optionally contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom;

R₃ is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF₃, methylthio, methylsulfonyl, CH₂OH, or CH₂OCH₃;

30 R₄ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, trifluoromethoxy, -CH₂OCH₃, -CH₂OCH₂CH₃, -CH₂CH₂OCH₃, -CH₂OF₃, CF₃, amino, nitro, -NH(C₁-C₄ alkyl), -N(CH₃)₂, -NHCOCH₃, -NHCONHCH₃, -SO_n(C₁-C₄ alkyl) wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C₁-C₄ alkyl), -CHO, cyano or -COO(C₁-C₄ alkyl) wherein said C₁-C₄ alkyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH₃, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)₂, -COO(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, chloro, cyano and nitro;

A2⁵
eat

10

R₁₂ is hydrogen or C₁-C₄ alkyl; and

15

20

25

6.

7.

30

9.

35

optionally contain one carbon-carbon double or triple bond, $-(C_1-C_4 \text{ alkylene})O(C_1-C_2 \text{ alkyl})$, C_1-C_3 hydroxyalkyl, hydroxy, formyl, $COO(C_1-C_2 \text{ alkyl})$, $-(C_1-C_2 \text{ alkylene})\text{amino}$, and $-(C(O))(C_1-C_4 \text{ alkyl})$.

11. A compound according to claim 9 wherein said substituents are selected, independently, from fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethyl, C_1-C_6 alkyl which may optionally be substituted with one hydroxy, C_1-C_4 alkoxy or fluoro group and which may optionally contain one carbon-carbon double or triple bond, $-(C_1-C_4 \text{ alkylene})O(C_1-C_2 \text{ alkyl})$, C_1-C_3 hydroxyalkyl, hydroxy, formyl, $COO(C_1-C_2 \text{ alkyl})$, $-(C_1-C_2 \text{ alkylene})\text{amino}$, and $-(C(O))(C_1-C_4 \text{ alkyl})$.

Sub
10 B2

12. A compound according to claim 1, wherein said compound is
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-diethyl-amine;
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-propyl-amine;
butyl-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine;
4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenylsulfanyl)-pyridine;
butyl-[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-amine;
[3,6-dimethyl-2-(2,4,6-trimethyl-phenylsulfanyl)-pyridin-4-yl]-ethyl-propyl-amine;
[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-ethyl-propyl-amine;
N4-(1-ethyl-propyl)-6-methyl-3-nitro-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,4-diamine;
3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-(2,2,2-trifluoro-ethyl)-amine;
N4-(1-ethyl-propyl)-6-methyl-N2-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine;
(N-(1-ethyl-propyl)-2-methyl-5-nitro-N'-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,6-
diamine;
[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-diethyl-amine;
(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-amine;
[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-
amine; or
[4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethylphenyl)-amine;
or a pharmaceutically acceptable salt of one of the above compounds.

Sub
31

13. A pharmaceutical composition for the treatment of (a) a disorder or condition the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder or condition selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias, including social phobia, agoraphobia, and specific phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus;

ulcer; diarrhea; stress-induced fever; human immunodeficiency virus infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies or addictions, including dependencies or addictions to alcohol, cocaine, heroin, benzodiazapines, or other drugs; drug or alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone; obesity; infertility; head trauma; spinal cord trauma; ischemic neuronal damage, including cerebral ischemia, for example cerebral hippocampal ischemia; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions, including porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, confinement dysfunction in chicken, sheering stress in sheep, and human-animal interaction stress in dogs; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; hypoglycemia, and Syndrome X in a mammal or bird, comprising an amount of a compound according to claim 1 that is effective in the treatment of such disorder or condition, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition according to claim 13 for the treatment of a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions; obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; and hypoglycemia in a mammal, including a human.

15. A method for the treatment of (a) a disorder or condition the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder or condition selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias, including social phobia, agoraphobia, and specific phobias; obsessive-

compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies or addictions, including dependencies or addictions to alcohol, cocaine, heroin, benzodiazapines, or other drugs; drug or alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone; obesity; infertility; head trauma; spinal cord trauma; ischemic neuronal damage, including cerebral ischemia, for example cerebral hippocampal ischemia; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions, including porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, confinement dysfunction in chicken, sheering stress in sheep, and human-animal interaction stress in dogs; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; hypoglycemia, and Syndrome X in a mammal or bird, comprising administering to a subject in need of said treatment an amount of a compound according to claim 1, that is effective in treating such disorder or condition.

16. A method according to claim 15 for the treatment of a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions; drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions; muscular spasms; urinary incontinence; senile

dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; and hypoglycemia in a mammal, including a human.

5 17. A method of treating a condition comprising administering a compound of claim 1 in an amount effective to treat said condition, wherein said condition is selected from the group consisting of:

- a) abnormal circadian rhythm;
- b) depression, further wherein a second compound for treating depression is administered, said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist; and
- 10 c) emesis.

18. The method of claim 17 wherein the condition is abnormal circadian rhythm, and the compound is combined with a second compound useful for treating a sleep disorder.

15 19. The method of claim 18, wherein said second compound is selected from the group consisting of tachykinin antagonists, agonists for GABA brain receptors, metalonergic compounds, GABA brain receptor agonists, 5HT₂ receptor antagonists, and D4 receptor binding.

20 20. The method of claim 17 wherein said condition is depression, and wherein said second compound having delayed action for treating depression is selected from the group consisting of selective serotonin reuptake inhibitors, tricyclic antidepressants, norepinephrine uptake inhibitors, lithium, bupropion, sertraline, fluoxetine, trazodone, and a tricyclic antidepressant selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine, and pharmaceutically acceptable salts and esters of the above-recited
25 compounds.

21. The method claim 17 wherein said condition is emesis, further comprising administering a second compound for treating emesis.

30 22. The method of claim 21 wherein said second compound for treating emesis is selected from the group consisting of tachykinin antagonists, 5HT₃ antagonists, GABA agonists, and substance P inhibitors.

23. A pharmaceutical composition for treating a condition comprising a compound of claim 1 in an amount effective to treat said condition and a pharmaceutically acceptable carrier, wherein said condition is selected from the group consisting of:

- a) abnormal circadian rhythm;
- 35 b) depression, further wherein a second compound for treating depression is administered, said second compound for treating depression

having an onset of action that is delayed with respect to that of said CRF antagonist; and

c) emesis.

24. A pharmaceutical composition according to claim 23, wherein the condition is
5 abnormal circadian rhythm, and the compound is combined with a second compound useful for treating a sleep disorder.

25. A pharmaceutical composition according to claim 24, wherein said second
compound is selected from the group consisting of tachykinin antagonists, agonists for GABA
brain receptors, metalonergic compounds, GABA brain receptor agonists, 5HT₂ receptor
10 antagonists, and D4 receptor binding .

26. A pharmaceutical composition according to claim 23 wherein said condition is
depression, and wherein said second compound having delayed action for treating depression
is selected from the group consisting of selective serotonin reuptake inhibitors, tricyclic
antidepressants, norepinephrine uptake inhibitors, lithium, bupropion, sertraline, fluoxetine,
15 trazodone, and a tricyclic antidepressant selected from the group consisting of imipramine,
amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine,
clomipramine, maprotiline, and carbamazepine, and pharmaceutically acceptable salts and
esters of the above-recited compounds.

27. A pharmaceutical composition according to claim 23 wherein said condition is
20 emesis, further comprising administering a second compound for treating emesis.

28. A pharmaceutical composition according to claim 27 wherein said second
compound for treating emesis is selected from the group consisting of tachykinin antagonists,
5HT₃ antagonists, GABA agonists, and substance P inhibitors.

Add
A4

Add
B7